Uncategorized

Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024

Sequana Medical NV announces data from its North American pivotal POSEIDON study of the alfapump® demonstrating significantly improved quality of life focused on ascites symptoms and physical functions compared to baseline, which is not seen in refractory ascites patients enrolled contemporaneously in the prospective NACSELD3 cohort.

Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024 Read More »

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon, Inc. announced the pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the public of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,000,000 shares of common stock at a purchase price of $6.249 per share,

Annexon Announces Pricing of $125 Million Underwritten Public Offering Read More »

Scroll to Top